Editor’s Note: Find the latest news and guidance on COVID-19 in Medscape Coronavirus Resource Center.

According to Novavax COVID-19 vaccine, could be the next shot to receive emergency authorization in the US to Politician.

The company is preparing to file FDA documentation in the coming weeks and could beat other vaccine manufacturers like AstraZeneca.

Public health officials and researchers consider the Novavax shot to be an option to fill supply gaps in the United States and around the world after safety issues with AstraZeneca and Johnson & Johnson vaccines arise.

“I think it will play a bigger role,” Lawrence Gostin, a professor of global health law at Georgetown University, told Politico.

“The Johnson & Johnson vaccine has been a reputable success and people are more hesitant to take it,” he said. “I think Novavax will be a reasonably significant player.”

Novavax is committed to providing 100 million doses in the US this year. However, the small drug manufacturer has never introduced any product to the market, Politico reported. The company has partnered with production companies around the world, including factories in the Czech Republic, Italy, India, Japan and South Korea, to create batches of vaccines. According to Novavax, it plans to produce 150 million doses a month during the second half of the year and Reuters.

At the same time, Biden administration officials are unsure of how quickly the company can increase production, Politico reported. The Serum Institute of India is expected to produce more than a billion doses of the Novavax trait this year, which will be distributed to the global vaccination effort. The institute is likely to apply for authorization for the vaccine in India once the FDA authorizes the shot in the United States, which could occur in May, according to on CNBC.

So far, the United States has not considered the firing of Novavax in COVID-19 response plans, Politico reported. The vaccine entered final-stage clinical trials months after the other candidates, but the results published in March showed that the vaccine has a similar efficacy index to the Pfizer and Moderna vaccines.

Researchers are also studying the effectiveness of the Novavax trait against variants of COVID-19. The results of the interim clinical trials showed that the vaccine was approximately 55% effective against variant B.1.351, which was first identified in South Africa. More information on variants can be posted when Novavax files for FDA approval, Politico reported.

If modified to target different variants, the Novavax feature could also be used as a reinforcement feature in the coming years.

“Everyone will need to be empowered,” Gregory Glenn, president of research and development at Novavax, told Politico.

“This is a viral respiratory disease, and we know from it grip that immunity to an infection is good for maybe 12 months, maybe 18 months, “he said.” After that, people are susceptible again. After that, we will have to strengthen. “


Politico: “The most promising coronavirus vaccine you’ve ever heard of.”

Reuters: “Novavax expects to produce 150 million doses of vaccine a month as early as May: CEO.”

CNBC: “Novavax expects FDA approval for the Covid vaccine as early as May, according to the CEO.”


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *